Possible UK surge

Alaska, immunization available to anyone 16 and older who lives or works in the state

US, past 7 days, 2.15 million doses per day

Fists dose, 61 million

Second dose, 32 million

Cases and deaths, CDC data

https://covid.cdc.gov/covid-data-tracker/#trends_dailytrendscases

Possible UK surge

https://www.bbc.co.uk/news/health-56334902

Prof Chris Whitty

Unlocking too quickly, substantial surge while a lot of people are not protected

A lot of people may think this is all over.

It is very easy to forget how quickly things can turn bad

Three weeks to build up immunity

So only the first four priority groups – the over-70s, health and care staff and the extremely clinical vulnerable

Nearly half of hospital admissions have been seen in the under-70s

Most transmission driven by younger people

Therefore, UK strategy will not impact spread for a while yet

UK, now

Cases, +5,766 (+ 40,600)
Down 24.5%

Deaths, + 231(+1,329)
Down 33.2%

Admitted, + 590 (+5,154)
Down 29.8%

Hospitalised, 9,418 (first time below 10,000 since 25th October)

Vaccinated

First dose, 22,592,528

Second dose, 1,181,431

UK is not using a one dose strategy

https://coronavirus.data.gov.uk/details/vaccinations

How do the Pfizer and Oxford AstraZeneca COVID-19 vaccines compare? And how do they affect different people?

https://covid.joinzoe.com/post/vaccines-webinar-immune-variation

March 8, 2021

N = 700,000

Injections, daily health reports

Pfizer vaccine first now, Oxford AstraZeneca as well

Both vaccines cause the body cells to produce the required antigen

Both vaccines induce really high levels of antibodies and T cells

Consistent with phase 3 data

Tim Spector

We see around a 70% reduction in mild disease after the vaccine, which is what we would expect. It’s really good news

Systemic side effects

Tiredness, headache, chills

First dose, Oxford AstraZeneca vaccine, 30%

Pfizer vaccine, 10%

Pfizer systemic effects worse if people have had CoViD infection

Pfizer side effects worse after second dose

After effects seem less than phase 3 data

Can’t associate measured immune responses with protection, eg. antibodies may be low, but protection good

Females, younger people, people who had a previous COVID infection, more likely to report after-effects from either vaccine

Not related to level of immunity generated

FDA

https://www.fda.gov/consumers/consumer-updates/why-you-should-not-use-ivermectin-treat-or-prevent-covid-19?utm_medium=email&utm_source=govdelivery

The FDA has received multiple reports of patients who have required medical support and been hospitalized after self-medicating with ivermectin intended for horses.

Ivermectin is not an anti-viral (a drug for treating viruses).

https://www.nature.com/articles/s41429-020-0336-z

Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen

Ivermectin proposes many potentials effects to treat a range of diseases

antimicrobial, antiviral, and anti-cancer properties

It is highly effective against many microorganisms including some viruses

In this comprehensive systematic review, antiviral effects of ivermectin are summarized including in vitro and in vivo studies over the past 50 years

Several studies reported antiviral effects of ivermectin on RNA viruses such as Zika, dengue, yellow fever, West Nile, Hendra, Newcastle, Venezuelan equine encephalitis, chikungunya, Semliki Forest, Sindbis, Avian influenza A, Porcine Reproductive and Respiratory Syndrome, Human immunodeficiency virus type 1, and severe acute respiratory syndrome coronavirus 2

Furthermore, there are some studies showing antiviral effects of ivermectin against DNA viruses such as Equine herpes type 1, BK polyomavirus, pseudorabies, porcine circovirus 2, and bovine herpesvirus 1

In vivo studies of animal models revealed a broad range of antiviral effects of ivermectin

Crump A, Ōmura S. Ivermectin, ‘wonder drug’ from Japan: the human use perspective. Proc Jpn Acad Ser B Phys Biol Sci. 2011;87:13–28. https://doi.org/10.2183/pjab.87.13.

Kircik LH, Del Rosso JQ, Layton AM, Schauber J. Over 25 years of clinical experience with ivermectin: an overview of safety for an increasing number of indications. J Drugs Dermatol. 2016;15:325–32.

Gonzalez Canga A, Sahagun Prieto AM, Diez Liebana MJ, Fernandez Martinez N, Sierra Vega M, Garcia Vieitez JJ. The pharmacokinetics and interactions of ivermectin in humans–a mini-review. AAPS J. 2008;10:42–6. https://doi.org/10.1208/s12248-007-9000-9.

Germany

https://www.washingtonpost.com/nation/2021/03/10/coronavirus-covid-live-updates-us/

Family doctors will be allowed to administer vaccine from April

3% currently fully vaccinated, since late December
AZ now used in over 65s

Thomas Mertens, Vaccination committee

Support for the Sputnik V

(European Union officials warn against)

Rolling review, Czech Republic, Hungary and Slovakia.

Source